Email
Print
The Progesterone Market is expected to grow at a CAGR of 12.9% over the forecast period of 2022-2027 to reach the estimated market size of $2,127.4 million by 2027. Progesterone is an endogenous steroid
secreted throughout the second half of the menstrual cycle by the corpus
luteum, a temporary endocrine gland the female body releases after ovulation.
Progesterone is responsible for maintaining pregnancy, menstrual cycle
regulation and embryogenesis. A leading U.S. Medical Magazine recently
commented that around 5% of menstruating women in the U.S. experience months of
a secondary form of amenorrhea, which can be ratified by progesterone usage. The growing role of pipeline drugs supported by the rising awareness of such
products in the field would propel the market to grow.
Progesterone Market Drivers
A Substantial Increase in the Cases of Amenorrhea, Breast and Uterine Cancer and AIDS:
Amenorrhea is the absence of menstruation, often defined as missing one or more menstrual periods. As per NCBI, 3-5% of adult women, in general, throughout the globe face this problem. An increase in the prevalence of breast cancer is expected to be a significant driver, as progesterone therapy can reduce breast pain and acts as a prime therapeutic choice. As per the American Cancer Society, about 30% of all new female cancers registered every year in the U.S. are breast cancers.
For More Queries About "Progesterone Market": https://www.industryarc.com/support.php?id=17892
Prevalent Infertility Rates Across the Regions:
Progesterone has been deterred as a key infertility treatment, as the hormone has been termed essential for maintaining pregnancy throughout the term and for getting pregnant. A growing trend in late pregnancies has proliferated the demand for progesterone, along with other infertility reasons. As per WHO's headline, infertility has been a global health issue. The available data suggests that around 48 million couples and 186 million individuals have infertility globally.
Approvals and Research
In September 2022, Scottish Medicines
Consortium (SMC) accepted the use of BIJUVE (1mg Estradiol/100mg Progesterone)
for use across the NHS in the region. In September 2022, new scientific papers
and recent advances assured that Hormone therapy can help relieve
menopause symptoms, the authors note that not all progestogens, medications
that protect the uterus against estrogen-stimulated cancer, carry equal breast
cancer risk.
The Major Players in the Market
The Major players in the Progesterone
Market include Teva Pharmaceuticals, Virtus, Lupin, CIPLA, Cadila, ALKEM Labs,
Aquatic Remedies Ltd, BioNPharma, Bluebell Pharmaceuticals and Estrella Life
Science Ltd.
Over the years, the pharmaceuticals giants have collaborated with leading research houses and contract research organizations to reduce the cost implication by maintaining a strong value-chain hold over the variables.